Maria Stepanova
Research Subjects
Maria Stepanova has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Zobair Younossi
Beatty Liver and Obesity Research Program Inova Health System Falls Church Virginia USA
9 shared publications - Andrei Racila
The Global NASH Council, Washington, DC
5 shared publications - Linda Henry
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA
4 shared publications - Fatema Nader
The Global Liver Council and the Global NASH/MASH Council, Washington DC, USA
3 shared publications - Issah Younossi
Center for Outcomes Research in Liver Disease, Washington DC, USA
3 shared publications - Andrei Racila
The Global NASH Council, Center for Outcomes Research in Liver Diseases, Wahington, District of Columbia, USA
2 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with health-related quality of life (HRQL) impairment, which can be exacerbated by pruritus, fatigue, and/or sleep disorders. We assessed the prevalence of significant pruritus, fatigue, and sleep disorders in patients with MASLD and evaluated their association with HRQL and work productivity loss. Methods: Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry. Clinical and HRQL (per CLDQ-MASH and WPAI:SHP questionnaires) data were analyzed according to the presence of significant pruritus, significant fatigue, and sleep disorders. Results: A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms. Patients with fatigue, pruritus, or sleep disorder were more likely to be female, have higher BMI, more metabolic comorbidities, and greater psychiatric burden. At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms. Multivariate analyses showed that significant pruritus and sleep disorders each independently predicted fatigue [OR=9.51 (8.0-11.3)] when both conditions were present. Pruritus was a strong predictor of sleep disorders [OR=2.90 (2.6-3.3)]. All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss. Conclusion: Clinically significant fatigue, pruritus, and sleep disorders are common in MASLD, having a negative impact on HRQL and a substantial economic burden.
- 22 October 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with health-related quality of life (HRQL) impairment, which can be exacerbated by pruritus, fatigue, and/or sleep disorders. We assessed the prevalence of significant pruritus, fatigue, and sleep disorders in patients with MASLD and evaluated their association with HRQL and work productivity loss. Methods: Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry. Clinical and HRQL (per CLDQ-MASH and WPAI:SHP questionnaires) data were analyzed according to the presence of significant pruritus, significant fatigue, and sleep disorders. Results: A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms. Patients with fatigue, pruritus, or sleep disorder were more likely to be female, have higher BMI, more metabolic comorbidities, and greater psychiatric burden. At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms. Multivariate analyses showed that significant pruritus and sleep disorders each independently predicted fatigue [OR=9.51 (8.0-11.3)] when both conditions were present. Pruritus was a strong predictor of sleep disorders [OR=2.90 (2.6-3.3)]. All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss. Conclusion: Clinically significant fatigue, pruritus, and sleep disorders are common in MASLD, having a negative impact on HRQL and a substantial economic burden.
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 24 September 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (5) , E70-E71
Erratum: Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Was not provided for this article.
- 26 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades
Cholestatic liver diseases [primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)] are important indications for liver transplantation (LT). Adult LT recipients with PBC or PSC were identified from the European Liver Transplant Registry (ELTR) and U.S. Scientific Registry of Transplant Recipients (SRTR) (2000–2022). We assessed temporal trends in PBC/PSC prevalence among the LT population and used Cox models to identify variables associated with post-transplant mortality in PBC/PSC. A total of 22,034 LT recipients were included (PBC n=8774; PSC n=13,260). HCC was present in 5.4% PBC, and cholangiocarcinoma in 2.4% PSC. PBC recipients had more ascites and hepatic encephalopathy, higher MELD scores (20±9 vs. 19±9) ( p p 0.05). The declines in PBC-LTs were observed in both SRTR and ELTR; PSC has shown a recent increase in ELTR: 4.9% to 7.3% ( p p p <0.05). Liver transplantations for PBC have declined, which may reflect improved medical therapy; PSC has remained stable, with recent increases in Europe. Three-year post-transplant survival exceeds 85% for both groups and continues to improve.
- 26 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades
Cholestatic liver diseases [primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)] are important indications for liver transplantation (LT). Adult LT recipients with PBC or PSC were identified from the European Liver Transplant Registry (ELTR) and U.S. Scientific Registry of Transplant Recipients (SRTR) (2000–2022). We assessed temporal trends in PBC/PSC prevalence among the LT population and used Cox models to identify variables associated with post-transplant mortality in PBC/PSC. A total of 22,034 LT recipients were included (PBC n=8774; PSC n=13,260). HCC was present in 5.4% PBC, and cholangiocarcinoma in 2.4% PSC. PBC recipients had more ascites and hepatic encephalopathy, higher MELD scores (20±9 vs. 19±9) ( p p 0.05). The declines in PBC-LTs were observed in both SRTR and ELTR; PSC has shown a recent increase in ELTR: 4.9% to 7.3% ( p p p <0.05). Liver transplantations for PBC have declined, which may reflect improved medical therapy; PSC has remained stable, with recent increases in Europe. Three-year post-transplant survival exceeds 85% for both groups and continues to improve.
- 31 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire
INTRODUCTION: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with a substantial symptom burden. However, no validated symptom-focused patient-reported outcome instrument exists for this population. We aimed to develop and validate the MASH Symptom Questionnaire. METHODS: We analyzed subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) from the global MASLD registry with clinical data and completed Chronic Liver Disease Questionnaire-MASH (CLDQ-MASH) instruments. For the new instrument development and preliminary validation, we used CLDQ-MASH items supplemented with symptom-related items from other generic instruments (development sample: n = 2,066) and expert input. A list of 50 symptom-related items was identified. After removal of redundancy, 36 items were retained and evaluated using exploratory factor analysis. Standard pipeline for validation of a patient-reported outcome instrument was applied. The instrument was validated using another independent validation sample from global MASLD registry (validation sample: n = 2,541). RESULTS: In the development phase, 36 items were distributed in 8 symptom domains: mental, cognitive, fatigue, systemic, abdominal, health distress, sleep disturbance, and peripheral symptoms domains. Seven of 8 domains demonstrated a Cronbach alpha >0.80 (high internal consistency); the remaining peripheral symptoms domain included diverse items. The domain scores significantly discriminated across histologic disease severity (early fibrosis vs. F2-F3 vs. cirrhosis), liver stiffness categories (20 kPa) in both development and independent validation samples. The instrument discriminated well based on nonhepatic comorbidities (type 2 diabetes, hypertension, psychiatric, sleep, pruritus, clinically overt fatigue, GERD, other GI disorders). Similar strong validation properties were noted in the independent validation sample. DISCUSSION: The 36-item, 8-domain CLDQ-MASH Symptom Questionnaire represents the first validated, disease-specific symptom questionnaire for patients with MASH showing good psychometric properties. With further external validation, the CLDQ-MASH Symptom Questionnaire has the potential to serve as a standardized tool in both clinical research and routine practice to comprehensively assess disease burden and treatment response.
- 31 July 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire
INTRODUCTION: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with a substantial symptom burden. However, no validated symptom-focused patient-reported outcome instrument exists for this population. We aimed to develop and validate the MASH Symptom Questionnaire. METHODS: We analyzed subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) from the global MASLD registry with clinical data and completed Chronic Liver Disease Questionnaire-MASH (CLDQ-MASH) instruments. For the new instrument development and preliminary validation, we used CLDQ-MASH items supplemented with symptom-related items from other generic instruments (development sample: n = 2,066) and expert input. A list of 50 symptom-related items was identified. After removal of redundancy, 36 items were retained and evaluated using exploratory factor analysis. Standard pipeline for validation of a patient-reported outcome instrument was applied. The instrument was validated using another independent validation sample from global MASLD registry (validation sample: n = 2,541). RESULTS: In the development phase, 36 items were distributed in 8 symptom domains: mental, cognitive, fatigue, systemic, abdominal, health distress, sleep disturbance, and peripheral symptoms domains. Seven of 8 domains demonstrated a Cronbach alpha >0.80 (high internal consistency); the remaining peripheral symptoms domain included diverse items. The domain scores significantly discriminated across histologic disease severity (early fibrosis vs. F2-F3 vs. cirrhosis), liver stiffness categories (20 kPa) in both development and independent validation samples. The instrument discriminated well based on nonhepatic comorbidities (type 2 diabetes, hypertension, psychiatric, sleep, pruritus, clinically overt fatigue, GERD, other GI disorders). Similar strong validation properties were noted in the independent validation sample. DISCUSSION: The 36-item, 8-domain CLDQ-MASH Symptom Questionnaire represents the first validated, disease-specific symptom questionnaire for patients with MASH showing good psychometric properties. With further external validation, the CLDQ-MASH Symptom Questionnaire has the potential to serve as a standardized tool in both clinical research and routine practice to comprehensively assess disease burden and treatment response.
- Open Access
- 26 May 2026
- Vol. 10 (6)
Development and validation of a disease-specific health-related quality of life questionnaire for alcohol-associated liver disease: The CLDQ-ALD.
Accurate assessment of health-related quality of life (HRQL) is essential in clinical research and therapeutic trials in alcohol-associated liver disease (ALD). The study aimed to develop and validate an ALD-specific HRQL instrument using a standard protocol for disease-specific HRQL instrument development. A comprehensive list of HRQL items was generated based on ALD patients' individual interviews and focus groups, existing HRQL instruments, and input from expert health care providers. Items were reduced through administration to patients with ALD, calculation of item impact scores, assessment of face validity, exploratory factor analysis, and evaluation of within-domain consistency and redundancy. The final Chronic Liver Disease Questionnaire (CLDQ)-ALD instrument underwent initial steps for psychometric validation. The initial questionnaire comprised 90 items. Across 2 rounds of item reduction, it was completed by 72 patients with ALD (32% 0.85 across all domains and >0.90 in 5 of 9 domains). Known-groups validity demonstrated mean score differences >0.5 (on a scale 1-7) in relevant domains by sex, presence of T2D, current alcohol use, depression, clinically overt fatigue, and cirrhosis. CLDQ-ALD version 1 is a disease-specific HRQL instrument for use in clinical research and therapeutic trials involving patients with ALD.
- 26 May 2026
- Vol. 10 (6)
Open AccessDevelopment and validation of a disease-specific health-related quality of life questionnaire for alcohol-associated liver disease: The CLDQ-ALD.
Accurate assessment of health-related quality of life (HRQL) is essential in clinical research and therapeutic trials in alcohol-associated liver disease (ALD). The study aimed to develop and validate an ALD-specific HRQL instrument using a standard protocol for disease-specific HRQL instrument development. A comprehensive list of HRQL items was generated based on ALD patients' individual interviews and focus groups, existing HRQL instruments, and input from expert health care providers. Items were reduced through administration to patients with ALD, calculation of item impact scores, assessment of face validity, exploratory factor analysis, and evaluation of within-domain consistency and redundancy. The final Chronic Liver Disease Questionnaire (CLDQ)-ALD instrument underwent initial steps for psychometric validation. The initial questionnaire comprised 90 items. Across 2 rounds of item reduction, it was completed by 72 patients with ALD (32% 0.85 across all domains and >0.90 in 5 of 9 domains). Known-groups validity demonstrated mean score differences >0.5 (on a scale 1-7) in relevant domains by sex, presence of T2D, current alcohol use, depression, clinically overt fatigue, and cirrhosis. CLDQ-ALD version 1 is a disease-specific HRQL instrument for use in clinical research and therapeutic trials involving patients with ALD.
- Open Access
- 26 February 2026
- Vol. 10 (3)
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Resmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom. Patients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%). MAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa <8.5 kPa] treated with 80 mg or 100 mg resmetirom or placebo or 100 mg open-label resmetirom. Baseline HRQL for MASH cirrhosis was significantly lower (up to -15% of score range) for all 6 domains of CLDQ-NAFLD and 13/17 domains of LDQoL (p<0.05). MASH cirrhosis, by week 24 of resmetirom treatment year 1, had improvements in Worry (CLDQ-NAFLD) and Health Distress (LDQoL) up to +4% of score range, sustained through week 52 and throughout year 2 (day 1, week 12, week 28) (p0.05). Early MASH patients with MRI-PDFF response experienced Abdominal and Worry score (up to +6%) improvements-greater than placebo or nonresponders. Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.
- 26 February 2026
- Vol. 10 (3)
Open AccessImprovement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Resmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom. Patients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%). MAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa <8.5 kPa] treated with 80 mg or 100 mg resmetirom or placebo or 100 mg open-label resmetirom. Baseline HRQL for MASH cirrhosis was significantly lower (up to -15% of score range) for all 6 domains of CLDQ-NAFLD and 13/17 domains of LDQoL (p<0.05). MASH cirrhosis, by week 24 of resmetirom treatment year 1, had improvements in Worry (CLDQ-NAFLD) and Health Distress (LDQoL) up to +4% of score range, sustained through week 52 and throughout year 2 (day 1, week 12, week 28) (p0.05). Early MASH patients with MRI-PDFF response experienced Abdominal and Worry score (up to +6%) improvements-greater than placebo or nonresponders. Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.
- Open Access
- 30 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.
- 30 April 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Open AccessGlobal patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease
Background: Noninvasive tests (NITs) are used to risk-stratify metabolic dysfunction–associated steatotic liver disease. The aim was to survey global patterns of real-world use of NITs. Methods: A 38-item survey was designed by the Global NASH Council. Providers were asked about risks for advanced fibrosis, which NITs (cutoff values) they use to risk-stratify liver disease, monitor progression, and which professional guidelines they follow. Results: A total of 321 participants from 43 countries completed the survey (54% hepatologists, 28% gastroenterologists, and 18% other). Of the respondents, 85% would risk-stratify patients with type 2 diabetes, obesity (82%), or abnormal liver enzymes (73%). Among NITs to rule out significant or advanced fibrosis, transient elastography (TE) and fibrosis-4 (FIB-4) were most used, followed by NAFLD Fibrosis Score, Enhanced Liver Fibrosis, and magnetic resonance elastography. The cutoffs for ruling out significant fibrosis varied considerably between practices and from guidelines, with only 50% using TE <8 kPa, 65% using FIB-4 <1.30 for age <65, and 41% using FIB-4 75% to monitor, and 66% would monitor (intermediate or high risk) annually. Finally, 65% follow professional guideline recommendations regarding NITs. Conclusions: In clinical practice, there is variability in NIT use and their thresholds. Additionally, there is suboptimal adherence to professional societies’ guidelines.
- Open Access
- 28 April 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (6) , e00844
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
INTRODUCTION: Despite being underappreciated, pruritus and fatigue are not uncommon in metabolic dysfunction-associated steatotic liver disease (MASLD). In this prospective registry-based study, we sought to evaluate the prevalence, predictors, and impact of these symptoms on patient-reported outcomes (PROs) in patients with MASLD from Türkiye, a country with one of the highest burdens of MASLD globally. METHODS: A total of 1,874 Turkish patients from the Global Liver Registry were included. Significant pruritus and fatigue were defined using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis and the Functional Assessment of Chronic Illness Therapy-Fatigue, respectively. PROs were assessed using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaire. RESULTS: The prevalence of significant pruritus and fatigue was 37% and 33%, respectively. Both symptoms were significantly associated with female sex, type 2 diabetes, depression, abdominal pain, and lack of regular exercise. Patients with these symptoms had significantly worse PROs, with impairments up to 31% (all P < 0.0001). Over 1–2 years, symptoms persisted in 47%–52% of patients with baseline pruritus and 33%−39% with baseline fatigue. Independent predictors of a higher likelihood of resolution of pruritus included the absence of fatigue at baseline and the lack of abdominal pain, with odds ratios of 0.36 (95% confidence interval: 0.22−0.59) and 0.60 (95% confidence interval: 0.39−0.91), respectively (both P < 0.05). DISCUSSION: Pruritus and fatigue are common in MASLD, significantly impairing PROs and often persisting over time. Regular assessment and management are essential to improve patients' well-being and functioning.
- 28 April 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (6) , e00844
Open AccessPruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry
INTRODUCTION: Despite being underappreciated, pruritus and fatigue are not uncommon in metabolic dysfunction-associated steatotic liver disease (MASLD). In this prospective registry-based study, we sought to evaluate the prevalence, predictors, and impact of these symptoms on patient-reported outcomes (PROs) in patients with MASLD from Türkiye, a country with one of the highest burdens of MASLD globally. METHODS: A total of 1,874 Turkish patients from the Global Liver Registry were included. Significant pruritus and fatigue were defined using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis and the Functional Assessment of Chronic Illness Therapy-Fatigue, respectively. PROs were assessed using the Chronic Liver Disease Questionnaire-nonalcoholic steatohepatitis, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Work Productivity and Activity Impairment: Specific Health Problem questionnaire. RESULTS: The prevalence of significant pruritus and fatigue was 37% and 33%, respectively. Both symptoms were significantly associated with female sex, type 2 diabetes, depression, abdominal pain, and lack of regular exercise. Patients with these symptoms had significantly worse PROs, with impairments up to 31% (all P < 0.0001). Over 1–2 years, symptoms persisted in 47%–52% of patients with baseline pruritus and 33%−39% with baseline fatigue. Independent predictors of a higher likelihood of resolution of pruritus included the absence of fatigue at baseline and the lack of abdominal pain, with odds ratios of 0.36 (95% confidence interval: 0.22−0.59) and 0.60 (95% confidence interval: 0.39−0.91), respectively (both P < 0.05). DISCUSSION: Pruritus and fatigue are common in MASLD, significantly impairing PROs and often persisting over time. Regular assessment and management are essential to improve patients' well-being and functioning.
- Open Access
- 13 May 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Validation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC
INTRODUCTION: Primary biliary cholangitis (PBC) is a chronic liver disease, leading to cirrhosis and impairment of patient-reported outcomes. We aimed to develop a PBC-specific version of the Chronic Liver Disease Questionnaire (CLDQ) instrument to assess health-related quality of life of patients with PBC. METHODS: From our Liver Database, we included patients with PBC who had CLDQ, clinicolaboratory data, and completed Short Form-36 and The Functional Assessment of Chronic Illness Therapy—Fatigue. The 29 items of CLDQ were subjected to item reduction, exploratory factor analysis, and fed into a standard instrument validation pipeline. RESULTS: Data were available for 108 patients with PBC: 57 ± 11 years, 7% male, 58% cirrhosis, and 24% decompensated cirrhosis (Child B and C). Of 29 CLDQ items, none met the exclusion criteria. Exploratory factor analysis (95% of variance) returned 7 factors. Based on evaluation of factor loadings and face validity, those factors yielded 7 domains (Diet, Emotion, Fatigue, Itch, Symptoms, Sleep, and Worry). Good to excellent internal consistency (Cronbach's α 0.85–0.93) was observed for 5/7 domains. For the remaining 2 domains (Diet and Itch), additional items obtained from patients, experts, and review of the literature were included. For 5 domains, known-group validity tests discriminated between patients with PBC with and without cirrhosis, advanced cirrhosis, and depression (P < 0.05 for 3–5 domains). The CLDQ-PBC domains were correlated with relevant domains of Short Form-36, CLDQ-PBC Fatigue correlated with Fatigue Scale of Functional Assessment of Chronic Illness Therapy—Fatigue (rho = +0.85), and CLDQ-PBC Worry domain negatively correlated with alkaline phosphatase (rho = −0.38, P = 0.0082). DISCUSSION: The CLDQ-PBC has been developed based on the original CLDQ. The new instrument has evidence for internal consistency and validity and is being fully validated using an external cohort.
- 13 May 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (9) , e1
Open AccessValidation of a Primary Biliary Cholangitis–Specific Version of Chronic Liver Disease Questionnaire: CLDQ-PBC
INTRODUCTION: Primary biliary cholangitis (PBC) is a chronic liver disease, leading to cirrhosis and impairment of patient-reported outcomes. We aimed to develop a PBC-specific version of the Chronic Liver Disease Questionnaire (CLDQ) instrument to assess health-related quality of life of patients with PBC. METHODS: From our Liver Database, we included patients with PBC who had CLDQ, clinicolaboratory data, and completed Short Form-36 and The Functional Assessment of Chronic Illness Therapy—Fatigue. The 29 items of CLDQ were subjected to item reduction, exploratory factor analysis, and fed into a standard instrument validation pipeline. RESULTS: Data were available for 108 patients with PBC: 57 ± 11 years, 7% male, 58% cirrhosis, and 24% decompensated cirrhosis (Child B and C). Of 29 CLDQ items, none met the exclusion criteria. Exploratory factor analysis (95% of variance) returned 7 factors. Based on evaluation of factor loadings and face validity, those factors yielded 7 domains (Diet, Emotion, Fatigue, Itch, Symptoms, Sleep, and Worry). Good to excellent internal consistency (Cronbach's α 0.85–0.93) was observed for 5/7 domains. For the remaining 2 domains (Diet and Itch), additional items obtained from patients, experts, and review of the literature were included. For 5 domains, known-group validity tests discriminated between patients with PBC with and without cirrhosis, advanced cirrhosis, and depression (P < 0.05 for 3–5 domains). The CLDQ-PBC domains were correlated with relevant domains of Short Form-36, CLDQ-PBC Fatigue correlated with Fatigue Scale of Functional Assessment of Chronic Illness Therapy—Fatigue (rho = +0.85), and CLDQ-PBC Worry domain negatively correlated with alkaline phosphatase (rho = −0.38, P = 0.0082). DISCUSSION: The CLDQ-PBC has been developed based on the original CLDQ. The new instrument has evidence for internal consistency and validity and is being fully validated using an external cohort.
- 27 August 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (2) , 416-422
Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients
Primary biliary cholangitis (PBC) is progressive and can cause end-stage liver disease necessitating a liver transplant (LT). PBC patients may be disadvantaged on LT waitlist due to MELD-based priority listing or other factors.
- 27 August 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (2) , 416-422
Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients
Primary biliary cholangitis (PBC) is progressive and can cause end-stage liver disease necessitating a liver transplant (LT). PBC patients may be disadvantaged on LT waitlist due to MELD-based priority listing or other factors.